EXPLAINING NONMARKET STRATEGIES IN WARTIME UKRAINE
SSRN Electronic Journal · 2026
DOI: 10.2139/ssrn.6576161 ↗At a glance
Journal article in SSRN Electronic Journal, 2026. Written by David Sieber-Mengel and 1 co-authors. 88 references.
Abstract (original language)
Russia's full-scale invasion disrupted the business environment of firms in Ukraine, forcing them to adapt operations and support the war effort. This study uses a qualitative case analysis to examine how and why firms changed their nonmarket strategies in wartime Ukraine. Drawing on 40 semi-structured interviews, participatory observations from five workshops, a field visit to Ukraine, and archival data, we develop a theoretical model of corporate warification, explaining firms' autonomous integration into the war effort. We show that violent conflict transforms stakeholder relationships, urging firms to contribute to the war by prioritizing war-specific Corporate Social Responsibility (CSR) over Corporate Political Activity (CPA) in this novel transitional context. Under conditions of weakened state capacity and homogenized societal demands, firms support government, military, and society, orienting nonmarket strategy toward national security as a collective goal. We identify martial CSR and propagandist CSR as conflict-specific corporate engagement forms and theorize responsibilization of business continuation as a mechanism blurring market-nonmarket boundaries. This study advances research on nonmarket strategy and CSR.
Cite
APA
Sieber-Mengel, D., & Winkler, D. M. (2026). EXPLAINING NONMARKET STRATEGIES IN WARTIME UKRAINE. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.6576161
Vancouver
Sieber-Mengel D, Winkler DM. EXPLAINING NONMARKET STRATEGIES IN WARTIME UKRAINE. SSRN Electronic Journal. 2026. doi:10.2139/ssrn.6576161
BibTeX
@article{SieberMengel2026,
author = {Sieber-Mengel, David and Winkler, Dorothee Maria},
title = {EXPLAINING NONMARKET STRATEGIES IN WARTIME UKRAINE},
journal = {SSRN Electronic Journal},
year = {2026},
doi = {10.2139/ssrn.6576161}
}
EUVIMED